HPAPIs require specialized handling and manufacturing facilities that protect the safety of employees and their environment. MilliporeSigma has been developing multi-step, complex, and highly potent compounds for more than 30 years and continues to be an industry leader in the development and custom manufacture of these components. They are used in novel cancer therapies, including antibody drug conjugates (ADCs), which are changing the landscape of cancer treatments.
HPAPIs are a critical element of targeted therapies due to their effective cell-killing abilities at low doses, resulting in reduced side effects for patients. “Increasing capacity at our state-of-the-art facility in Verona, WI, will allow us to meet the need for these key cancer treatment components.”Ĭancer is the second leading cause of death worldwide. Lower-doses of these therapies reduce the negative side effects for patients who are taking on this critical fight,” said Dirk Lange, head of life science services, life science business sector of Merck KGaA. “There is an increasing demand for HPAPIs due to their effectiveness against cancer at lower doses and the trend towards more targeted therapeutics. This new $65 million, 70,000 square foot facility brings 50 new jobs to the area.
and Canada Life Science business of Merck KGaA, has doubled its high-potent active pharmaceutical ingredients ( HPAPI ) production capacity with the expansion of its facility in Verona, near Madison, WI.
0 kommentar(er)
